Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma
暂无分享,去创建一个
T. Hocking | T. Naoe | H. Kantarjian | J. Cortes | E. Jabbour | L. Medeiros | M. J. You | M. Nakatochi | C. Yin | J. Jorgensen | H. Kiyoi | F. Hayakawa | K. Sugimoto | W. Wang | S. Hu | C. Yin | K. Shimada | Shimin Hu | M. Suguro | Z. Chen | S. Shimada | Zi Chen | Wei Lien Wang | Akihiro Hirakawa | Ichiro Takeuchi | Takashi Tokunaga | Yusuke Takagi | Akihiko Sakamoto | Tomohiro Aoki | Sigeo Nakamura | Masao Seto | Akihiro Tomita
[1] S. Hofer,et al. Intravascular large B‑cell lymphoma , 2016, memo - Magazine of European Medical Oncology.
[2] T. McDonnell,et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. , 2015, Blood.
[3] Martin C. Müller,et al. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy , 2015, PloS one.
[4] J. Hasford,et al. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death , 2015, Annals of Hematology.
[5] R. Silver,et al. Management of chronic myeloid leukemia in blast crisis , 2015, Annals of Hematology.
[6] K. Spiekermann,et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV , 2015, Leukemia.
[7] C. Gambacorti-Passerini,et al. How I treat newly diagnosed chronic myeloid leukemia in 2015 , 2015, American journal of hematology.
[8] T. Hocking,et al. Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis , 2014, Cancer science.
[9] H. Kantarjian,et al. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia , 2014, Leukemia & lymphoma.
[10] Francis R. Bach,et al. SegAnnDB: interactive Web-based genomic segmentation , 2014, Bioinform..
[11] K. Greulich-Bode,et al. On the Power of Additional and Complex Chromosomal Aberrations in CML , 2012, Current genomics.
[12] R. Hehlmann. How I treat CML blast crisis. , 2012, Blood.
[13] M. Baccarani,et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. , 2012, Blood.
[14] Martin C. Müller,et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.
[15] A. Hochhaus. Educational session: managing chronic myeloid leukemia as a chronic disease. , 2011, Hematology. American Society of Hematology. Education Program.
[16] S. Kimura,et al. Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma , 2011, Annals of Hematology.
[17] M. Baccarani,et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. , 2010, Cancer genetics and cytogenetics.
[18] Miguel Vicente-Manzanares,et al. Non-muscle myosin II takes centre stage in cell adhesion and migration , 2009, Nature Reviews Molecular Cell Biology.
[19] T. Naoe,et al. Presentation and management of intravascular large B-cell lymphoma. , 2009, The Lancet. Oncology.
[20] F. Cavalli,et al. The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma , 2008, British journal of haematology.
[21] T. Naoe,et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Djokic. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5 , 2008 .
[23] S. Kimura,et al. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. , 2007, Mayo Clinic proceedings.
[24] E. Campo,et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Naoe,et al. Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy , 2007, International journal of hematology.
[26] Peter J Houghton,et al. Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.
[27] T. Naoe,et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice , 2007, Leukemia.
[28] J. Radich. The Biology of CML blast crisis. , 2007, Hematology. American Society of Hematology. Education Program.
[29] M. Okigaki,et al. Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab. , 2006, Clinical nephrology.
[30] Mamoru Ito,et al. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. , 2005, Cancer Science.
[31] T. Hara,et al. Lymph Node Fibroblastic Reticular Cells Construct the Stromal Reticulum via Contact with Lymphocytes , 2004, The Journal of experimental medicine.
[32] H. Tagawa,et al. Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.
[33] A. López-Guillermo,et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[35] M Hummel,et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.
[36] S. Gill,et al. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. , 2003, The American journal of medicine.
[37] Mamoru Ito,et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.
[38] B. Johansson,et al. Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.
[39] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[40] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] T. Suchi,et al. An Asian variant of intravascular large B‐cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B‐cell lymphoma associated with haemophagocytic syndrome , 2000, British journal of haematology.
[42] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[43] G. Arrigoni,et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. , 2000, Human pathology.
[44] S. Narumiya,et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.
[45] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.